News

Retatrutide at ADA 2026: Triple-Agonist vs. Tir...

ADA 2026 may bring new retatrutide data, but head-to-head trials against tirzepatide are still missing. We examine what clinicians need to know about

Retatrutide at ADA 2026: Triple-Agonist vs. Tir...

ADA 2026 may bring new retatrutide data, but head-to-head trials against tirzepatide are still missing. We examine what clinicians need to know about

Tirzepatide vs. GLP-1: Why Telehealth Shifts to Dual-Action

Tirzepatide vs. GLP-1: Why Telehealth Shifts to...

Telehealth platforms are adopting tirzepatide and retatrutide for weight loss, citing higher efficacy than GLP-1 monotherapy, but female-specific data and long-term safety remain limited.

Tirzepatide vs. GLP-1: Why Telehealth Shifts to...

Telehealth platforms are adopting tirzepatide and retatrutide for weight loss, citing higher efficacy than GLP-1 monotherapy, but female-specific data and long-term safety remain limited.